Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Below Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. SPY
4. IQMX
5. EROC
6. MSTR
7. SEER
8. NVDA
9. RIVN
10. TSLA

Go back to Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Below Guidance

Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital

March 15, 2019 6:51 AM EDT

BMO Capital analyst Gary Nachman lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $21.00 (from $24.00) while maintaining a Outperform rating following relatively in-line 4Q18 results.

guidance is appropriately conservative and should be very achievablemanagement sounded confident in several potential nondilutive financing options

... More